Cipla Limited announced on July 27, 2026, that it has received U.S. FDA approval for its Generic Advair Diskus®, a combination therapy for asthma and COPD. This approval covers all three strengths: 100/50 mcg, 250/50 mcg, and 500/50 mcg. The product is a therapeutically equivalent version of the branded Advair Diskus® and is expected to launch in Q2 FY 2026-27 in the United States. This marks a significant milestone for Cipla’s U.S. respiratory portfolio.
FDA Greenlights Generic Advair Diskus®
Cipla Limited, a leading global pharmaceutical company, announced today, July 27, 2026, a significant achievement with the U.S. Food and Drug Administration (FDA) granting approval for its Abbreviated New Drug Application (ANDA) for Generic Advair Diskus®. This groundbreaking approval encompasses all three available strengths of the medication: 100/50 mcg, 250/50 mcg, and 500/50 mcg.
Therapeutic Equivalence and Market Entry
The newly approved Generic Advair Diskus® is recognized as a therapeutically equivalent alternative to the widely prescribed Advair Diskus®. This combination therapy is essential for managing asthma and chronic obstructive pulmonary disease (COPD). The U.S. market for fluticasone propionate and salmeterol inhalation powder is substantial, estimated at approximately $908 million according to IQVIA. This approval represents Cipla’s first dry powder inhaler (DPI) approval originating from its U.S.-based manufacturing network, signaling a major advancement in the company’s expansion of complex respiratory capabilities within the United States. The product is anticipated to be launched in the second quarter of the fiscal year 2026-27.
Strategic Significance and Future Outlook
Achin Gupta, Managing Director & Global CEO of Cipla Limited, commented on the approval, stating, “At Cipla, we’re passionate about respiratory care given our long-standing expertise. This approval reinforces our commitment to expanding access to complex therapies in the U.S. and highlights our strength in developing and scaling sophisticated inhalation products through integrated capabilities.” The company’s vertically integrated inhalation platform supports this product launch, underscoring Cipla’s dedication to bolstering U.S. manufacturing for complex respiratory treatments. Marc Falkin, Chief Executive Officer of Cipla North America, added, “This approval marks our first dry powder inhaler from our New York facility and reflects our targeted investments in building differentiated inhalation manufacturing capabilities in the U.S. It strengthens our ability to provide reliable, high-quality supply in an important and competitive category.”
Source: BSE
